RET and neoplasm: His initial poorly differentiated ED group #2 tumor was sequenced and showed an aggressive signature with pathogenic mutations in NF2, ATR, CREBBP and KMT2D. A nonsense mutation in RET receptor tyrosine kinase at Y1090* was also detected.